Risk factors for sexual and erectile dysfunction in hiv-infected men: The role of protease inhibitors

AIDS

Volumn 24, Issue 2, 2010, Pages 255-264

  Moreno Pérez, Oscar ^a   Escoín, Corina ^b   Serna Candel, Carmen ^c   Picó, Antonio ^a   Alfayate, Rocio ^d   Merino, Esperanza ^b   Reus, Sergio ^b   Boix, Vicente ^b   Sanchez Paya, José ^b   Portilla, Joaquin ^b  

^a Department of Endocrinology and Nutrition ^*  (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d Hormone Laboratory   (Spain)

Author keywords

Antiretroviral therapy; Erectile dysfunction; HIV; Prevalence; Risk factors; Sexual dysfunction

Indexed keywords

ABACAVIR; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ADULT; AGED; AGING; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; ERECTILE DYSFUNCTION; HEALTH STATUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK FACTOR; SEXUAL DYSFUNCTION; SMOKING; THERAPY EFFECT; TREATMENT DURATION; VIRUS LOAD; WAIST HIP RATIO;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; ERECTILE DYSFUNCTION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; VIRAL LOAD;

EID: 74249107904     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328334444b     Document Type: Article

References (31)

1. Cohan P, Korenman SG. Erectile dysfunction. J Clin Endocrinol Metab 2001; 86:2191-2194.
2. Beutel ME, Weidner W, Brahler E. Epidemiology of sexual dysfunction in the male population. Andrologia 2006; 38:115-121.
3. Cohan GR. HIV-associated hypogonadism. AIDS Read 2006; 16:341-354.
4. Lamba H, Goldmeier D, Mackie NE, Scullard G. Antiretroviral therapy is associated with sexual dysfunction and with increased serum oestradiol levels in men. Int J STD AIDS 2004; 15:234-237.
5. Rhoden EL, Telöken C, Sogari PR, Vargas Souto CA. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res 2002; 14:245-250.
6. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, Rodriguez-Vela L, Jimenez-Cruz JF, Burgos-Rodriguez R. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 2001; 166:569-574.
7. Crum-Cianflone NF, Bavaro M, Hale B, Amling C, Truett A, Brandt C, et al. Erectile dysfunction and hypogonadism among men with HIV. AIDS Patient Care STDS 2007; 21:9-19.
8. Ende AR, Lo Re V 3rd, DiNubile MJ, Mounzer K. Erectile dysfunction in an urban HIV-positive population. AIDS Patient Care STDS 2006; 20:75-78.
9. Beckman TJ, Abu-Lebdeh HS, Mynderse LA. Evaluation and medical management of erectile dysfunction. Mayo Clin Proc 2006; 81:385-390.
10. Colson AE, Keller MJ, Sax PE, Pettus PT, Platt R, Choo PW. Male sexual dysfunction associated with antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 30:27-32.
11. Schrooten W, Colebunders R, Youle M, Molenberghs G, Dedes N, Koitz G, et al., Eurosupport Study Group. Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. AIDS 2001; 15:1019-1023.
12. Sollima S, Osio M, Muscia F, Gambaro P, Alciati A, Zucconi M, et al. Protease inhibitors and erectile dysfunction. AIDS 2001; 15:2331-2333.
13. Guaraldi G, Luzi K, Murri R, Granata A, De Paola M, Orlando G, et al. Sexual dysfunction in HIV-infected men: role of antiretroviral therapy, hypogonadism and lipodystrophy. Anti-vir Ther 2007; 12:1059-1065.
14. Cove J, Petrak J. Factors associated with sexual problems in HIV-positive gay men. Int J STD AIDS 2004; 15:732-736.
15. Moreno-Perez O, Pico A, Portilla J. Hypogonadism, erectile dysfunction and endothelial dysfunction among HIV-infected men. Med Clin (Barc) 2009; 132:311-321.
16. Cofrancesco J Jr, Whalen JJ 3rd, Dobs AS. Testosterone replacement treatment options for HIV-infected men. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:254-265.
17. Guay AT. ED2: erectile dysfunction U endothelial dysfunction. Endocrinol Metab Clin North Am 2007; 36:453-463.
18. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49:822-830.
19. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999; 54: 346-351.
20. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49:1239-1242.
21. Moore C, Huebler D, Zimmermann T, Heinemann LA, Saad F, Thai do M. The aging males' symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 2004; 46:80-87. (Pubitemid 38748514)
22. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG, HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361:726-735. (Pubitemid 36293626)
23. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 1988; 8:77-100.
24. CollazosJ. Sexual dysfunction in the highly active antiretroviral therapy era. AIDS Rev 2007; 9:237-245.
25. Collazos J, Mart́inez E, Mayo J, Ibarra S. Sexual dysfunction in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31:322-326. (Pubitemid 35278633)
26. Colson A, Sax P, Keller M, Platt R, Choo P. Sexual dysfunction in protease inhibitor recipients [abstract #A63]. In: 7th CROI; February 2000; San Francisco, California.
27. Lallemand F, Salhi Y, Linard F, Giami A, Rozenbaum W. Sexual dysfunction in 156 ambulatory HIV-infected men receiving highly active antiretroviral therapy combinations with and without protease inhibitors. J Acquir Immune Defic Syndr 2002; 30:187-190.
28. Asboe D, Catalan J, Mandalia S, Dedes N, Florence E, Schrooten W, et al. Sexual dysfunction in HIV-positive men is multi-factorial: a study of prevalence and associated factors. AIDS Care 2007; 19:955-965.
29. BhasinS, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline.JClinEndocrinol Metab 2006; 91:1995-2010.
30. Rowland DL, Thornton JA, Burnett AL. Recognizing the risk of erectile dysfunction in a urology clinic practice. BJU Int 2005; 95:1034-1038.
31. Taylor MJ, Rudkin L, Hawton K. Strategies for managing anti-depressant-induced sexual dysfunction: systematic review of randomised controlled trials. J Affect Disord 2005; 88:241-254.